...with vehicle. Next steps could include testing the compound in mouse models of BRAF-mutant melanoma. BioMed Valley Discoveries Inc....

...MAPK1; ERK-2)/MAPK3 (ERK-1) inhibitor. The candidate has Fast Track designation from FDA to treat melanoma. BioMed Valley Discoveries Inc....
...Phase II dose; pharmacokinetics and preliminary tumor response Status: Phase I data Milestone: NA Jaime De Leon BVD-523 ulixertinib BioMed Valley Discoveries Inc. MAP...

...at the negotiating table." Funding the gap Freedman said Gladstone modeled Cure Network Ventures after BioMed Valley...
...unlike Cure Network, BVD doesn’t rely on partnerships with venture philanthropists because its funding from BioMed Valley...
...is appropriately carved out," he said. Companies and Institutions Mentioned BioMed Valley Corp., Kansas City, Mo. BioMed Valley Discoveries Inc....

...7(35); doi:10.1038/scibx.2014.1037 Published online Sept. 11, 2014 Patented by The Johns Hopkins University; licensed to BioMed Valley Discoveries Inc....

...II AstraZeneca; Bayer Refametinib (BAY 86-9766) Pancreatic and biliary duct cancers MEK1; MEK2 Phase I/II BioMed Valley Discoveries Inc....

...SciBX 4(36); doi:10.1038/scibx.2011.1029 Published online Sept. 15, 2011 Patent applications filed; available for licensing from BioMed Valley Discoveries Inc....
...research organization established and funded by the Stowers Institute for Medical Research Contact: Saurabh Saha, BioMed Valley Discoveries Inc....